, Nous comparons ici l'efficacité et l'innocuité d'un biosimilaire du rituximab, Truxima ®
République de Corée) avec le rituximab de référence, MabThera ® , chez des patients atteints de SEP ,
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med. 14 févr, vol.358, issue.7, pp.676-88, 2008. ,
,
, Rituximab versus fingolimod after natalizumab in multiple sclerosis patients, Ann Neurol. juin, vol.79, issue.6, pp.950-958, 2016.
,
, Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy, Neurology, vol.15, issue.20, pp.2074-81, 2016.
Comparative effectiveness of rituximab relative to IFN-? or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry, Mult Scler, vol.24, issue.8, pp.1087-95, 2018. ,
Efficacy of rituximab in refractory RRMS, Mult Scler, vol.25, issue.6, p.36, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02066062
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience, Mult Scler, p.1352458519872889, 2019. ,
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis, JAMA Neurol. 1 mars, vol.76, issue.3, p.81, 2019. ,
,
, Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura, Br J Haematol. juin, vol.185, issue.5, pp.912-919, 2019.
Bracing for the biosimilar wave, Nat Rev Drug Discov, p.1 ,
Biosimilars and market access: a question of comparability and costs?, Target Oncol. déc, vol.7, issue.4, p.31, 2012. ,
Biosimilar medicines and cost-effectiveness, Clinicoecon Outcomes Res, vol.3, pp.29-36, 2011. ,
Biosimilars: part 1: proposed regulatory criteria for FDA approval ,
, P T. mai, vol.38, issue.5, pp.270-87, 2013.
, Biosimilars: Company Strategies
, Capture Value from the Biologics Market. Pharmaceuticals (Basel). 12 déc, vol.5, issue.12, pp.1393-408, 2012.
The state of the art in the development of biosimilars ,
, Clin Pharmacol Ther. mars, 2012.
,
, Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies, Mult Scler. 1 août, vol.24, issue.9, pp.1224-1257, 2018.
, Cette motivation était principalement économique (prix du biosimilaire inférieur à celui du MabThera ® , respect du contrat de bon usage qui incite à la prescription de biosimilaires,?) mais aucune étude n'avait montré la sécurité d'utilisation et l'efficacité de ce biosimilaire dans la
, Nous montrons ici que le Truxima ® semble présenter la même tolérance et efficacité que le MabThera ® dans la SEP, avec l'avantage de présenter un coût inférieur. Pour autant, il devient difficile de justifier de l'utilisation de ce biosimilaire dans la SEP en hors-AMM du fait que l'ocrelizumab possède maintenant cette autorisation
, Il serait intéressant à l'avenir de comparer ces deux anti-CD20 dans la SEP
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med. 14 févr, vol.358, issue.7, pp.676-88, 2008. ,
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial, Neurology. 8 juin, vol.74, issue.23, pp.1860-1867, 2010. ,
,
, Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial, Ann Neurol. mars, vol.63, issue.3, p.400, 2008.
,
, Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebocontrolled, multicentre trial, Lancet, vol.378, issue.9805, pp.1779-87, 2011.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.19, issue.3, pp.221-255, 2017. ,
Biosimilar medicines and cost-effectiveness, Clinicoecon Outcomes Res, vol.3, pp.29-36, 2011. ,
Biosimilars and market access: a question of comparability and costs?, Target Oncol. déc, vol.7, issue.4, p.31, 2012. ,
Biosimilars: part 1: proposed regulatory criteria for FDA approval ,
, P T. mai, vol.38, issue.5, pp.270-87, 2013.
Biosimilars: Company Strategies to Capture Value from the, Biologics Market. Pharmaceuticals (Basel). 12 déc, vol.5, issue.12, pp.1393-408, 2012. ,
The state of the art in the development of biosimilars ,
, Clin Pharmacol Ther. mars, 2012.
Multiple Sclerosis, N Engl J Med, vol.11, issue.2, p.80, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01480156
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives, Autoimmun Rev. juill, vol.18, issue.7, pp.665-72, 2019. ,
B-cells in multiple sclerosis, Int MS J. nov, vol.13, issue.3, p.90, 2006. ,
,
, Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol. juin, vol.47, issue.6, pp.707-724, 2000.
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsingremitting multiple sclerosis is effective and safe, J Neurol. mars, vol.266, issue.3, p.34, 2019. ,
A reassessment of the distribution of multiple sclerosis ,
, Acta Neurol Scand. févr, vol.51, issue.2, p.36, 1975.
The prevalence of multiple sclerosis in the world: an update, Neurol Sci. Apr, vol.22, issue.2, pp.117-156, 2001. ,
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis, J Neurol Neurosurg Psychiatry, vol.82, issue.10, pp.1132-1173, 2011. ,
,
, Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study, PLoS ONE, vol.10, issue.7, p.132033, 2015.
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain. mars, vol.131, pp.808-825, 2008. ,
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology. avr, vol.46, issue.4, pp.907-918, 1996. ,
Multiple sclerosis, N Engl J Med. 28 sept, vol.343, issue.13, p.52, 2000. ,
,
, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, p.71, 2009.
Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology. 15 juill, vol.83, issue.3, pp.278-86, 2014. ,
Corticosteroids in the treatment of multiple sclerosis ,
, Acta Neurol Scand, Suppl, vol.73, issue.189, p.80, 2009.
Multiple Sclerosis: Immunopathology and Treatment Update, Brain Sci, vol.7, issue.2017 ,
,
, Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study, Journal of Immunology Research, 2018.
,
Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland, PLOS ONE. 14 mai, vol.13, issue.5, p.197415, 2018. ,
Mechanisms of action of CD20 antibodies, Am J Cancer Res, vol.2, issue.6, p.90, 2012. ,
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review, PLoS ONE, vol.8, issue.7, p.66308, 2013. ,
Experience with longterm rituximab use in a multiple sclerosis clinic, Mult Scler J Exp Transl Clin. déc, vol.2, p.2055217316672100, 2016. ,
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients, Ann Neurol. juin, vol.79, issue.6, pp.950-958, 2016. ,
,
, Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy, Neurology, vol.15, issue.20, pp.2074-81, 2016.
Comparative effectiveness of rituximab relative to IFN-? or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry, Mult Scler, vol.24, issue.8, pp.1087-95, 2018. ,
Efficacy of rituximab in refractory RRMS, Mult Scler, vol.25, issue.6, p.36, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02066062
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience, Mult Scler, p.1352458519872889, 2019. ,
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis, JAMA Neurol. 1 mars, vol.76, issue.3, p.81, 2019. ,
Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura, Br J Haematol. juin, vol.185, issue.5, pp.912-919, 2019. ,
Bracing for the biosimilar wave, Nat Rev Drug Discov, p.1 ,
Biosimilars and Inflammatory Bowel Diseases ,
Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: quality issues (revision 1) -PDF Free Download, BioDrugs. 15 juill, vol.30, issue.4, pp.339-51, 2016. ,
Guidelineon-similar-biological-medicinal-products-containing-biotechnology-derived-proteinsas-active-substance-quality-issues-revision-1.html 43. Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: non-clinical and clinical issues, p.13 ,
,
,
,
, Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies, Mult Scler, vol.24, issue.9, pp.1224-1257, 2018.
Rituximab for relapsingremitting multiple sclerosis, Cochrane Database Syst Rev. 6 déc, issue.12, p.9130, 2013. ,
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab, Neurology. 12 juill, vol.87, issue.2, pp.141-148, 2016. ,